---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-010872"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:33:32.511850+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DiaMedica reports Q1 2022 cash burn of $3.9M; ReMEDy2 stroke trial sites more than double

## Summary
- Cash & investments $41M at March 31 (Dec 31: $45.1M); working capital $40.7M; cash runway into 2024.
- Net cash used in ops $3.9M (Q1 2021: $4.3M); R&D exp $2.0M (-$0.4M); G&A exp $1.6M (+$0.4M).
- ReMEDy2 stroke trial active sites more than doubled to 9; slower enrollment due to COVID staffing & discharge logistics.
- REDUX CKD trial fully enrolled (79 patients); last visit in March 2022; final analysis ongoing.

## SEC filing metadata
- accession: 0001437749-22-010872
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774922010872/0001437749-22-010872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774922010872/dmtp20220503_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-010872
- JSON: https://secwatch.observer/filing/0001437749-22-010872.json
- Plain text: https://secwatch.observer/filing/0001437749-22-010872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.